Bioburden Testing Market Worth $2.01 Billion By 2026 | CAGR: 13.7%

Bioburden Testing Market Growth & Trends

The global bioburden testing market size is expected to reach USD 2.01 billion by 2026, expanding at a CAGR of 13.7% during the forecast period, according to a new report by Grand View Research, Inc. The market is expected to showcase upward trend in the forthcoming years owing to growing concerns about product safety. This has led to various government initiatives to promote microbiological safety testing tools.

A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.

Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Merck is planning to invest USD 16 billion in R&D over the next five years, in addition to its annual investment of USD 7 billion. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.

Request a free sample copy or view report summary: Bioburden Testing Market Report

Bioburden Testing Market Report Highlights

• On the basis of product, consumables segment dominated the market in 2018 owing to a wide use of culture media and reagents and kits
• PCR instruments facilitate rapid analysis of bacterial bioburden, thus, fostering high market growth
• Aerobic count testing held significant market share in 2018 due to easy isolation of aerobic bacteria by culture media
• Raw material testing is anticipated to showcase lucrative growth during the forecast period owing to the increasing number of product recalls and concern regarding product quality
• On the basis of end use, pharmaceutical and biotechnology companies dominated the market in 2018 owing to the high growth of this industry
• The number of CMOs is increasing significantly, which has led to a rise in outsourcing services, thus, driving the segment growth
• North America held the largest revenue share in 2018 due to high R&D spending by key companies and high healthcare spending in the U.S.
• Some of the key manufacturers in the bioburden testing market include Charles River Laboratories International, Inc.; SGS SA; Merck KGaA; Becton, Dickinson and Company; and Wuxi Apptec